Stockreport

Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity

Cardiff Oncology, Inc.  (CRDF) 
PDF SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel [Read more]